Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Mem. Inst. Oswaldo Cruz ; 112(11): 756-759, Nov. 2017. tab
Artículo en Inglés | LILACS | ID: biblio-894849

RESUMEN

BACKGROUND Mycobacterium tuberculosis (MTB) is one of the most significant causes of mortality and morbidity. Early diagnose is important especially in multiple drug resistant tuberculosis to avoid transmission. Traditional techniques requires at least one to three weeks for diagnosis of tuberculosis. Diagnostic delays with multiple drug resistant tuberculosis are associated with worse clinical outcomes and increased transmission The Xpert MTB/RIF assay is one of the new diagnostic device for the diagnosis of tuberculosis and rapid detection of rifampicin resistance. OBJECTIVE We assessed the performance of Xpert MTB/RIF assay for detecting rifampicin resistance using phenotypic drug susceptibility tests as automated BD MGIT 960. METHODS Total of 2136 specimens were included in the study. Xpert MTB/RIF testing was performed on samples, using version 4 cartridges, according to the manufacturer's recommendations. The MTBC culture and first-line phenotypic DST were performed in automated BD MGIT 960 (Becton & Dickinson, USA) according to the recommendations of the manufacturer. Agar proportion was used in the case of inconsistency for rifampicin resistance. FINDINGS Thirty-four samples (19 respiratory and 15 nonrespiratory samples) were determined as positive for M. tuberculosis complex by Xpert MTB/RIF (Cepheid GeneXpert® System, USA). Xpert MTB/RIF assay detected 4/34 (11.7%) specimens as rifampicin resistant. One of the rifampicin resistant isolates was determined susceptible in MGIT 960 automated system. This isolate was also tested with agar proportion method and found susceptible to rifampicin. MAIN CONCLUSION The Xpert MTB/RIF assay can be used as first-line assay for the detection of M. tuberculosis. However, microbiologists must be aware of the limitations of the assay.


Asunto(s)
Humanos , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Antibióticos Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Fenotipo , Sensibilidad y Especificidad
2.
Mem. Inst. Oswaldo Cruz ; 111(7): 454-459, tab, graf
Artículo en Inglés | LILACS | ID: lil-787556

RESUMEN

In this study we evaluated the crystal violet decolorization assay (CVDA) for detection of minimum inhibitory concentration (MIC) of antituberculosis drugs. 53 isolates were tested in this study and 13 of them were multidrug resistant (MDR) isolates. The antibiotics concentrations were 2-0.06 mg/L for isoniazid (INH) and rifampicin (RIF) and were 16-0.25 mg/L for streptomycin (STM) and ethambutol (EMB). Crystal violet (CV-25 mg/L) was added into the microwells on the seventh day of incubation and incubation was continued until decolorization. Decolorization of CV was the predictor of bacterial growth. Overall agreements for four drugs were detected as 98.1%, and the average time was detected as 9.5 ± 0.89 day after inoculation. One isolate for INH and two isolates for STM were determined resistant in the reference method, but susceptible by the CVDA. One isolate was susceptible to EMB by the reference method, but resistant by the CVDA. All results were concordant for RIF. This study shows that CVDA is a rapid, reliable and suitable for determination of MIC values of Mycobacterium tuberculosis. And it can be used easily especially in countries with limited-sources.


Asunto(s)
Humanos , Antituberculosos/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Antituberculosos/administración & dosificación , Bioensayo , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Etambutol/administración & dosificación , Etambutol/farmacología , Violeta de Genciana/química , Indicadores y Reactivos/química , Isoniazida/administración & dosificación , Isoniazida/farmacología , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/crecimiento & desarrollo , Rifampin/administración & dosificación , Rifampin/farmacología , Estreptomicina/administración & dosificación , Estreptomicina/farmacología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología
3.
Mem. Inst. Oswaldo Cruz ; 106(3): 378-380, May 2011. tab
Artículo en Inglés | LILACS | ID: lil-589052

RESUMEN

The susceptibility of 49 Mycobacterium tuberculosis clinical isolates to isoniazid (INH) and rifampisin (RIF) (28 multi-drug resistant-tuberculosis samples) was determined by a nitrate reductase assay (NRA) on blood agar. Agreement between the NRA and other testing methods was found to be 93.8 percent for both INH and RIF. The sensitivity, specificity, positive predictive value and negative predictive value for INH were 92.8 percent, 94.2 percent, 86.6 percent and 97 percent, respectively. The sensitivity, specificity, positive predictive value and negative predictive value for RIF were 90.4 percent, 96.4 percent, 95 percent and 93.1 percent. In conclusion, we show here that blood agar can be used effectively for the NRA test.


Asunto(s)
Humanos , Antituberculosos , Farmacorresistencia Bacteriana Múltiple , Isoniazida , Mycobacterium tuberculosis , Rifampin , Agar , Pruebas de Sensibilidad Microbiana , Nitrato-Reductasa , Valor Predictivo de las Pruebas , Sensibilidad y Especificidad , Tuberculosis Resistente a Múltiples Medicamentos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA